General characteristics of colon cancer cases and associations with MSI
| . | MSS, n = 437 (%) . | MSI, n = 49 (%) . | OR (95% CI) . | |||
|---|---|---|---|---|---|---|
| Age (median, 65 y) | ||||||
| <65 | 212 (49) | 17 (35) | Reference | |||
| ≥65 | 225 (51) | 32 (65) | 1.77 (0.96-3.290) | |||
| Gender | ||||||
| Female | 212 (49) | 29 (59) | Reference | |||
| Male | 225 (51) | 20 (41) | 0.65 (0.36-1.18) | |||
| Race | ||||||
| Blacks | 204 (47) | 14 (29) | Reference | |||
| Whites | 233 (53) | 35 (71) | 2.19 (1.14-4.18) | |||
| Family history | ||||||
| No | 350 (80) | 35 (71) | Reference | |||
| Yes | 87 (20) | 14 (29) | 1.61 (0.83-3.12) | |||
| Location of tumor | ||||||
| Distal | 165 (45) | 8 (17) | Reference | |||
| Proximal | 205 (55) | 38 (83) | 3.82 (1.74-8.42) | |||
| Stage of cancer at time of diagnosis | ||||||
| Local | 145 (39) | 17 (39) | Reference | |||
| Regional | 210 (59) | 26 (59) | 1.06 (0.55-2.02) | |||
| Distant | 41 (2) | 1 (2) | 0.21 (0.03-1.61) | |||
| Alcohol (category of use) | ||||||
| None | 306 (71) | 27 (56) | Reference | |||
| Lower half | 55 (13) | 8 (17) | 1.65 (0.71-3.82) | |||
| Upper half | 73 (17) | 13 (27) | 2.02 (0.99-4.10) | |||
| Smoking status | ||||||
| Never | 184 (42) | 9 (19) | Reference | |||
| Former | 184 (42) | 26 (54) | 2.89 (1.32-6.33) | |||
| Current | 67 (15) | 13 (27) | 3.97 (1.62-9.70) | |||
| NSAID use during past 5 y | ||||||
| Never | 48 (11) | 10 (21) | Reference | |||
| Occasionally | 177 (40) | 23 (48) | 0.62 (0.28-1.40) | |||
| Frequently | 212 (49) | 15 (31) | 0.34 (0.14-0.80) | |||
| Total calcium intake | ||||||
| Quartile 1 | 113 (26) | 7 (15) | Reference | |||
| Quartile 2 | 109 (25) | 12 (25) | 1.78 (0.68-4.68) | |||
| Quartile 3 | 105 (24) | 16 (33) | 2.46 (0.97-6.22) | |||
| Quartile 4 | 107 (25) | 13 (27) | 1.96 (0.75-5.10) | |||
| Vitamin/supplement use | ||||||
| No/occasional | 264 (61) | 29 (62) | Reference | |||
| Regularly | 166 (39) | 18 (38) | 0.99 (0.53-1.83) | |||
| . | MSS, n = 437 (%) . | MSI, n = 49 (%) . | OR (95% CI) . | |||
|---|---|---|---|---|---|---|
| Age (median, 65 y) | ||||||
| <65 | 212 (49) | 17 (35) | Reference | |||
| ≥65 | 225 (51) | 32 (65) | 1.77 (0.96-3.290) | |||
| Gender | ||||||
| Female | 212 (49) | 29 (59) | Reference | |||
| Male | 225 (51) | 20 (41) | 0.65 (0.36-1.18) | |||
| Race | ||||||
| Blacks | 204 (47) | 14 (29) | Reference | |||
| Whites | 233 (53) | 35 (71) | 2.19 (1.14-4.18) | |||
| Family history | ||||||
| No | 350 (80) | 35 (71) | Reference | |||
| Yes | 87 (20) | 14 (29) | 1.61 (0.83-3.12) | |||
| Location of tumor | ||||||
| Distal | 165 (45) | 8 (17) | Reference | |||
| Proximal | 205 (55) | 38 (83) | 3.82 (1.74-8.42) | |||
| Stage of cancer at time of diagnosis | ||||||
| Local | 145 (39) | 17 (39) | Reference | |||
| Regional | 210 (59) | 26 (59) | 1.06 (0.55-2.02) | |||
| Distant | 41 (2) | 1 (2) | 0.21 (0.03-1.61) | |||
| Alcohol (category of use) | ||||||
| None | 306 (71) | 27 (56) | Reference | |||
| Lower half | 55 (13) | 8 (17) | 1.65 (0.71-3.82) | |||
| Upper half | 73 (17) | 13 (27) | 2.02 (0.99-4.10) | |||
| Smoking status | ||||||
| Never | 184 (42) | 9 (19) | Reference | |||
| Former | 184 (42) | 26 (54) | 2.89 (1.32-6.33) | |||
| Current | 67 (15) | 13 (27) | 3.97 (1.62-9.70) | |||
| NSAID use during past 5 y | ||||||
| Never | 48 (11) | 10 (21) | Reference | |||
| Occasionally | 177 (40) | 23 (48) | 0.62 (0.28-1.40) | |||
| Frequently | 212 (49) | 15 (31) | 0.34 (0.14-0.80) | |||
| Total calcium intake | ||||||
| Quartile 1 | 113 (26) | 7 (15) | Reference | |||
| Quartile 2 | 109 (25) | 12 (25) | 1.78 (0.68-4.68) | |||
| Quartile 3 | 105 (24) | 16 (33) | 2.46 (0.97-6.22) | |||
| Quartile 4 | 107 (25) | 13 (27) | 1.96 (0.75-5.10) | |||
| Vitamin/supplement use | ||||||
| No/occasional | 264 (61) | 29 (62) | Reference | |||
| Regularly | 166 (39) | 18 (38) | 0.99 (0.53-1.83) | |||